How Does the COVID-19 Antiviral Medications Workflow Compare to the Traditional Antiviral Production Pipeline
The discussion focuses on comparing the traditional antiviral production pipeline to the workflow used for producing COVID-19 antiviral medications. Dr. Kishor Wasan shares insights into how COVID-19 vaccine research differs from past practices in antiviral and antibiotic production. The conversation aims to highlight the differences and similarities in treatment development for COVID-19 versus other viruses.
This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.
Key takeaways
Researchers are learning more about COVID-19 to effectively combat it.
Differences are noted in the COVID-19 vaccine production versus traditional antiviral pipelines.
Get featured
Want to get featured in MarketScale Sciences?
Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.
As the COVID-19 pandemic continues to progress researchers and scientists are starting to learn more about the virus in order to effectively combat it. One of those lessons is how the COVID-19 virus compares to other viruses when it comes to developing treatments. Justin Honore talked to Dr. Kishor Wasan, PH.D.,FAAPS, FCAHS, FCSPS, Chief Medical & Scientific Officer at Skymount Medical and a Distinguished University Scholar Adjunct Professor at the University of British Columbia about how COVID-19 vaccine research and production compare to the traditional antiviral and antibiotic production pipeline.
Your experts belong here
Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.
About the author
